
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Medical Center of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable
End-Stage Heart Failure Sends News that Biopeutics Enters Phase 3 Clinical Trials
Details : Eubeatline (alprostadil), is a Prostaglandin E1 agonist, which is being evaluated for the treatment of severe heart failure in adults.
Product Name : Eubeatline
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 18, 2023
Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Medical Center of Vienna
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Alprostadil
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI
Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acute Kidney Injury.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 27, 2022
Lead Product(s) : Alprostadil
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alprostadil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Advanz Pharma
Deal Size : $96.0 million
Deal Type : Acquisition
Details : Advanz get the rights to a portfolio of alprostadil products including, Prostavasin, Viridal, Vasaprostan and Edex, which consists of injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive dis...
Product Name : Prostavasin
Product Type : Miscellaneous
Upfront Cash : $96.0 million
April 01, 2020
Lead Product(s) : Alprostadil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Advanz Pharma
Deal Size : $96.0 million
Deal Type : Acquisition

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alprostadil
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Advanz Pharma
Deal Size : $98.0 million
Deal Type : Agreement
Details : The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
Product Name : Prostavasin
Product Type : Miscellaneous
Upfront Cash : $84.0 million
March 06, 2020
Lead Product(s) : Alprostadil
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Advanz Pharma
Deal Size : $98.0 million
Deal Type : Agreement

Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The Safety and Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers
Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Arterial Occlusive Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 13, 2018
Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Raynaud Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 29, 2014
Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Prostaglandin E1 in Outpatients With Intermittent Claudication
Details : Alprostadil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arterial Occlusive Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 21, 2010
Lead Product(s) : Alprostadil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All